Leukemia, Myeloid, Acute Clinical Trial
Official title:
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.
Status | Recruiting |
Enrollment | 450 |
Est. completion date | December 2022 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologically or pathologically confirmed diagnosis of AML based on WHO classification that has relapsed after, or is refractory to, two, three, or four prior induction regimens that may have included intensive chemotherapy (e.g., "7+3" cytarabine and daunorubicin), epigenetic therapy (i.e., azacitidine or decitabine), or targeted therapy (e.g., FLT-3, IDH-1/2, BCL-2, monoclonal antibody). (Relapse is defined as reemergence of =5% leukemia blasts in bone marrow or =1% blasts in peripheral blood =90 days after first CR or CR without complete platelet recovery (CRp). Refractory AML is defined as persistent disease =28 days after initiation of intensive induction therapy (up to two induction cycles) or relapse <90 days after first CR or CRp. Refractory disease for patients undergoing hypomethylating agent induction is defined as lack of remission following at least 2 cycles of epigenetic therapy without reduction in bone marrow blast status.) Patients with a history of IPSS-R high or very high risk MDS that transformed to AML during treatment with hypomethylating drugs and then relapse following or are refractory to a subsequent AML induction regimen may be enrolled as Second Salvage AML patients. Additionally, patients with a history of MPN in accelerated phase (MPN-AP) or high-risk primary myelofibrosis (PMF) that transformed to AML during treatment with hypomethylating drugs and then relapse following or are refractory to a subsequent AML induction regimen may be enrolled as Second Salvage AML patients. 2. Aged = 18 years. 3. ECOG Performance Status of 0, 1 or 2. 4. Adequate clinical laboratory values (i.e., plasma creatinine <2.5 x upper limit of normal (ULN) for the institution, bilirubin <2.5 x ULN, alanine transaminase (ALT) and aspartate transaminase (AST) =2.5 x ULN). 5. Absence of active central nervous system (CNS) involvement by leukemia. Patients with previously diagnosed CNS leukemia are eligible if the CNS leukemia is under control and intrathecal treatment may continue throughout the study. 6. Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. 7. Signed informed consent prior to the start of any study specific procedures. 8. Women of child-bearing potential must have a negative serum or urine pregnancy test. 9. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration. Exclusion Criteria: 1. The interval from prior treatment to time of study drug administration is < 2 weeks for cytotoxic agents or < 5 half-lives for noncytotoxic agents. Exceptions: Use of hydroxyurea is allowed before the start of study and is to be discontinued prior to the initiation of study treatment. At the investigator's discretion, for patients with significant leukocytosis that develops during the early treatment cycles, hydroxyurea may be administered. The hydroxyurea should be discontinued as soon as clinically appropriate. 2. Any >grade 1 persistent clinically significant toxicities from prior chemotherapy. 3. Inadequate Cardiac (left ventricular ejection fraction =40%) function. 4. White blood cell (WBC) count >15,000/µL (Note: Patients considered for possible venetoclax-containing regimen must have WBC =10k/µL prior to initiating venetoclax treatment). 5. For patients with prior hematopoietic stem cell transplant (HSCT): 1. Less than 3 months since HSCT 2. Acute Graft versus Host Disease (GvHD) >Grade 1 3. Chronic GvHD >Grade 1 6. Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance. 7. A pregnant or lactating woman. 8. Current malignancies of another type. Exceptions: Patients may participate if they have previously treated and currently controlled prostate cancer, or adequately treated in situ cervical cancer or basal cell skin cancer, or other malignancies with no evidence of disease for 2 years or more. 9. Patient has acute promyelocytic leukemia (APL). 10. Patients with known HIV, active HBV or active HCV infection (note: testing for these infections is not required). For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. 11. Documented or known clinically significant bleeding disorder. |
Country | Name | City | State |
---|---|---|---|
United States | Georgia Cancer Center at Augusta University | Augusta | Georgia |
United States | O'Neal Comprehensive Cancer Center | Birmingham | Alabama |
United States | University of Vermont Medical Center | Burlington | Vermont |
United States | Gabrail Cancer Center | Canton | Ohio |
United States | Novant Health Cancer Institute - Elizabeth (Hematology) | Charlotte | North Carolina |
United States | University of Virginia Health System | Charlottesville | Virginia |
United States | Rush University | Chicago | Illinois |
United States | University of Cincinnati Cancer Center | Cincinnati | Ohio |
United States | Seidman Cancer Center, University Hospitals, Cleveland Medical Center | Cleveland | Ohio |
United States | UT Southwestern | Dallas | Texas |
United States | Decatur Memorial Hospital-Cancer Care Specialists of Central IL | Decatur | Illinois |
United States | Henry Ford Cancer Institute | Detroit | Michigan |
United States | UF-Health Cancer Center Gainesville | Gainesville | Florida |
United States | Banner MD Anderson | Gilbert | Arizona |
United States | East Carolina University | Greenville | North Carolina |
United States | Prisma Health Cancer Institute | Greenville | South Carolina |
United States | Loyola University Medical Center | Hines | Illinois |
United States | Baylor College of Medicine | Houston | Texas |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Franciscan Health Indianapolis | Indianapolis | Indiana |
United States | University of California | Irvine | California |
United States | The University of Mississippi Medical Center | Jackson | Mississippi |
United States | Baptist MD Anderson | Jacksonville | Florida |
United States | UF-Health Jacksonville | Jacksonville | Florida |
United States | Ochsner Benson Cancer Center | Jefferson | Louisiana |
United States | Vidant Oncology | Kinston | North Carolina |
United States | University of KY- Markey Cancer Center | Lexington | Kentucky |
United States | UCLA | Los Angeles | California |
United States | Norton Cancer Institute | Louisville | Kentucky |
United States | Tulane University | New Orleans | Louisiana |
United States | AdventHealth Medical Group Blood and Marrow Transplant at Orlando | Orlando | Florida |
United States | HonorHealth (VGPCC Cancer Transplant Institute) | Scottsdale | Arizona |
United States | Avera Medical Group | Sioux Falls | South Dakota |
United States | Multicare Institute for Research and Innovation | Spokane | Washington |
United States | The University of Arizona Cancer Center | Tucson | Arizona |
United States | New York Medical College | Valhalla | New York |
United States | The University of Kansas Cancer Center | Westwood | Kansas |
United States | Novant Health Cancer Institute - Forsyth (Hematology) | Winston-Salem | North Carolina |
United States | Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Delta-Fly Pharma, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete remission (CR) rate | The rate of CR based on International Working Group (IWG) Guidelines for bone marrow and blood response | 3 years | |
Primary | Duration of complete remission | Number of days from time of initial CR until disease recurrence or death | 3 years | |
Secondary | The rate of complete remission (CR) + (complete remission with incomplete hematologic recovery) CRi+ (complete remission with partial hematologic recovery) CRp | CR as above including neutrophil granulocyte count > 0.5x10^9/L & platelet count > 50x10^9/L | 3 years | |
Secondary | The duration of complete remission (CR) + (complete remission with incomplete hematologic recovery) CRi+ (complete remission with partial hematologic recovery) CRp | CR as above including neutrophil granulocyte count > 0.5x10^9/L & platelet count > 50x10^9/L + platelet count < 100x10^9/L | 3 years | |
Secondary | Overall survival | Number of days from date of first dose to date of death | 3 years | |
Secondary | Transition rate to hematopoietic stem cell transplantation (HSCT) | Number of subjects who transition to HSCT | 3 years | |
Secondary | Overall response rate (ORR) | The rate of CR + CRi + CRp + PR | 3 years | |
Secondary | Duration overall response | The duration of CR + CRi + CRp + PR | 3 years | |
Secondary | Rate of disease related co-morbidities | Number and severity of expected leukemia-related adverse events | 3 years | |
Secondary | Adverse events | Number of patients with adverse events | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05319587 -
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04090736 -
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
|
Phase 3 | |
Completed |
NCT01617226 -
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
|
Phase 2 | |
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00640796 -
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
|
Phase 1 | |
Completed |
NCT00458250 -
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
|
Phase 1 | |
Active, not recruiting |
NCT05424380 -
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
|
Phase 1 | |
Completed |
NCT01690624 -
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
|
Phase 1 | |
Recruiting |
NCT05471700 -
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05016063 -
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Early Phase 1 | |
Not yet recruiting |
NCT04450784 -
ObServatory Children Acute RElated Therapy Leukemia
|
||
Recruiting |
NCT04265963 -
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT04968860 -
Oral Health Condition and Quality of Life in Children With Leukemia
|
||
Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT02841540 -
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
|
Phase 1 | |
Recruiting |
NCT05453903 -
A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
|
Phase 1 | |
Completed |
NCT03720366 -
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
|
Phase 1 | |
Withdrawn |
NCT04230564 -
Acute Myeloid Leukemia Real World Treatment Patterns
|
||
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 |